MR-OPERA: A Multicenter/Multivendor Validation of Magnetic Resonance Imaging–Only Prostate Treatment Planning Using Synthetic Computed Tomography Images

Publication date: 1 November 2017
Source:International Journal of Radiation Oncology*Biology*Physics, Volume 99, Issue 3
Author(s): Emilia Persson, Christian Gustafsson, Fredrik Nordström, Maja Sohlin, Adalsteinn Gunnlaugsson, Karin Petruson, Niina Rintelä, Kristoffer Hed, Lennart Blomqvist, Björn Zackrisson, Tufve Nyholm, Lars E. Olsson, Carl Siversson, Joakim Jonsson
PurposeTo validate the dosimetric accuracy and clinical robustness of a commercially available software for magnetic resonance (MR) to synthetic computed tomography (sCT) conversion, in an MR imaging–only workflow for 170 prostate cancer patients.Methods and MaterialsThe 4 participating centers had MriPlanner (Spectronic Medical), an atlas-based sCT generation software, installed as a cloud-based service. A T2-weighted MR sequence, covering the body contour, was added to the clinical protocol. The MR images were sent from the MR scanner workstation to the MriPlanner platform. The sCT was automatically returned to the treatment planning system. Four MR scanners and 2 magnetic field strengths were included in the study. For each patient, a CT-treatment plan was created and approved according to clinical practice. The sCT was rigidly registered to the CT, and the clinical treatment plan was recalculated on the sCT. The dose distributions from the CT plan and the sCT plan were compared according to a set of dose-volume histogram parameters and gamma evaluation. Treatment techniques included volumetric modulated arc therapy, intensity modulated radiation therapy, and conventional treatment using 2 treatment planning systems and different dose calculation algorithms.ResultsThe overall (multicenter/multivendor) mean dose differences between sCT and CT dose distributions were below 0.3% for all evaluated organs and targets. Gamma evaluation showed a mean pass rate of 99.12% (0.63%, 1 SD) in the complete body volume and 99.97% (0.13%, 1 SD) in the planning target volume using a 2%/2-mm global gamma criteria.ConclusionsResults of the study show that the sCT conversion method can be used clinically, with minimal differences between sCT and CT dose distributions for target and relevant organs at risk. The small differences seen are consistent between centers, indicating that an MR imaging–only workflow using MriPlanner is robust for a variety of field strengths, vendors, and treatment techniques.



from Cancer via ola Kala on Inoreader http://ift.tt/2fcHpip
via IFTTT